The company, which invests in royalties on approved and late-stage biopharmaceutical products, filed for the biggest IPO of the year thus far. The news follows biotech's biggest IPO of 2020, China-based Legend Biotech's $424 million Nasdaq debut.
Both Livongo and Health Catalyst held their IPOs today and saw their stock price soar more than 40 percent in early trading.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company, which will be listed on the Nasdaq exchange under the ticker symbol "LVGO," offers tech-enabled solutions that help to monitor and manage people with chronic conditions like diabetes, hypertension and behavioral health issues.
The company, whose FDA-approved products include the myeloma drug Darzalex and the chronic leukemia drug Arzerra, hopes to launch its own proprietary product by 2025.
The French company, developing a drug to treat nonalcoholic steatohepatitis, or NASH, announced the pricing of its shares at $20.32 apiece.
The company, one of several developing drugs for the growing fatty liver disease, said in an SEC filing that it would sell its shares at $26.33 apiece.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company, which had previously sought to use a legal but potentially risky workaround, expects to raise $276 million.
The offering closes on Tuesday and follows a string of very large IPOs by biotech companies over the last couple of months. Moderna's February $500 million Series G round valued the company at $7 billion.
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.
The London-based biotech would trade on the Nasdaq under the ticker symbol ORTX. The move comes two months after it closed a $150 million Series C and five months after it acquired a gene therapy portfolio from GSK.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The filing comes one week after the company, founded earlier this year with a $300 million Series A round by two former Kite executives, raised $120 million in a private financing.
The company, which has already raised more than $500 million in venture capital funding, would trade on the NASDAQ under the ticker symbol "GH."
The unassuming llama may be the star of a new $75 million initial public offering, announced Monday by the Netherlands and Belgium-based biotech argenx.
Lemhi Ventures and Nasdaq led the round. They were joined by previous investors Goldman Sachs and Hospital Corp. of America.
Novel obesity treatment company EnteroMedics (NASDAQ:ETRM) that has survived a close brush with disaster recorded revenue for the first time since it was incorporated nearly eight years ago. On Tuesday, the company reported revenue of about $123,000 in the first quarter of the year that were garnered from the sale of its implantable neuromodulation system — Maestro […]